Comparative Efficacy of Two Different β‐Blockers on 24‐Hour Blood Pressure Control

Sarafidis, Pantelis A.; Bogojevic, Zvezdana; Basta, Emad; Kirstner, Emily; Bakris, George L.

doi:10.1111/j.1751-7176.2008.08021.x

Cited by 15 publications

(12 citation statements)

References 25 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the β-blockers, atenolol once daily does not provide adequate BP control during the nighttime and early-morning periods (45). Sarafidis et al (46) showed that atenolol was less effective in sustaining 24-h and early-morning BP reductions compared with metoprolol succinate in HTN patients treated with once-daily hydrochlorothiazide. It is possible that differences in outcome between atenolol-based and other therapies may be the result of inadequate dosing of atenolol, a medication that may not be effective for the entire 24-h period.…”

Section: Advantages Of Ambulatory Bp Measurements Over Office Measurementioning

confidence: 99%

Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Hypertension

Grossman

2013

Diabetes Care

101

View full text Add to dashboard Cite

Section: Advantages Of Ambulatory Bp Measurements Over Office Measurementioning

confidence: 99%

Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Hypertension

Grossman

2013

Diabetes Care

101

View full text Add to dashboard Cite

“…These drug profiles of atenolol may be the cause for its relatively weak blood pressure-lowering effect and the blood pressure instability. On the other hand, metoprolol or bisoprolol have been shown to be more effective in sustaining 24-hour and early morning BP reductions as compared with atenolol [15, 16]. …”

Section: Hypertensionmentioning

confidence: 99%

Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease

Tomiyama

Yamashina

2014

International Journal of Hypertension

View full text Add to dashboard Cite

This minireview provides current summaries of beta-blocker use in the management of hypertension and/or chronic kidney disease. Accumulated evidence suggests that atenolol is not sufficiently effective as a primary tool to treat hypertension. The less-than-adequate effect of beta-blockers in lowering the blood pressure and on vascular protection, and the unfavorable effects of these drugs, as compared to other antihypertensive agents, on the metabolic profile have been pointed out. On the other hand, in patients with chronic kidney disease, renin-angiotensin system blockers are the drugs of first choice for achieving the goal of renal protection. Recent studies have reported that vasodilatory beta-blockers have adequate antihypertensive efficacy and less harmful effects on the metabolic profile, and also exert beneficial effects on endothelial function and renal protection. However, there is still not sufficient evidence on the beneficial effects of the new beta-blockers.

show abstract

“…5 Some studies have found that atenolol does not provide 24 h of ß-blockade. 6,7 As Wallace et al note, Freestone found that atenolol has more predictable ß-blockade at 24 h than does metoprolol. 8 However, Freestone's group also reported that atenolol's reduction of the pulse during exercise was less at 24 h than at 3 [1/2] h after dosing.…”

Section: To the Editormentioning

confidence: 99%